Cryoport vs Standard BioTools
CYRX and LAB side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How CYRX and LAB compare
Cryoport is the larger company, worth 4.1 times as much as Standard BioTools ($1.0B against $252M).
Cryoport grew revenue faster over the last twelve months (11.8% versus −4.8% for Standard BioTools).
Standard BioTools keeps more of each dollar of sales as profit, with a net margin of 100% compared with −21.5% at Cryoport.
Standard BioTools scores higher on the StockData Score (12 against 10 for Cryoport), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | CYRX | LAB |
|---|---|---|
| Size and price | ||
| Market cap | $1.0B | $252M |
| Share price | $20.56 | $0.643 |
| Change, 1 year | 141% | −45.0% |
| Change, 5 years | −71.5% | −85.7% |
| Beta (5Y) | 1.92 | 1.53 |
| Employees | 738 | 389 |
| StockData Score | ||
| Total score | 10 | 12 (better) |
| Valuation score | 1 | 4 (better) |
| Growth score | 2 (better) | 0 |
| Performance score | 3 | 3 |
| Health score | 4 | 5 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | – | 2.9× |
| P/S | 5.4× | 3.0× (better) |
| P/B | 2.2× | 0.5× (better) |
| FCF yield | −1.8% (better) | −32.7% |
| Fair value | $16.42 | $4.90 |
| Margin of safety | −25.2% | 86.9% (better) |
| Growth | ||
| Revenue growth (TTM) | 11.8% (better) | −4.8% |
| Revenue growth, 5Y average | 17.5% (better) | −9.2% |
| Net income growth (TTM) | −158% | – |
| EPS growth (TTM) | −178% | – |
| Profitability | ||
| Gross margin | 46.9% | 50.5% (better) |
| Operating margin | −20.0% (better) | −113% |
| Net margin | −21.5% | 100% (better) |
| FCF margin | −9.8% (better) | −97.6% |
| Return on equity | −8.3% | 17.6% (better) |
| Return on invested capital | −32.9% (better) | −60.8% |
| Financial health | ||
| Debt / equity | 0.00 (better) | 0.00 |
| Interest coverage | −18.3× | – |
| Current ratio | 2.04 | 9.10 (better) |
| Altman Z-score | 1.46 (better) | −0.34 |
| Piotroski F-score | 5 (better) | 3 |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 93.9% | 75.4% |
| Held by insiders | 3.6% | 70.2% |
| Insider net buying, 12 months | −$4.6M | $550K (better) |
| Superinvestors holding | – | 1 |
| Short interest, % of float | 7.1% | 1.9% |
Go deeper
- CYRX stock overview
- CYRX income statement
- CYRX valuation and score
- LAB stock overview
- LAB income statement
- LAB valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.